deltatrials
Completed PHASE2 NCT01875380

Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer

A Phase II Study of Single-agent Regorafenib in the First Line Treatment of Frail and/or Unfit for Polychemotherapy Patients With Metastatic Colorectal Cancer (mCRC)

Sponsor: Bayer

Conditions Colorectal Neoplasms Metastatic Disease
Interventions Regorafenib
Updated 5 times since 2017 Last updated: Jul 31, 2017 Started: Jun 30, 2013 Primary completion: Apr 30, 2016 Completion: Apr 30, 2016

Listed as NCT01875380, this PHASE2 trial focuses on Colorectal Neoplasms and Metastatic Disease and remains completed. Sponsored by Bayer, it has been updated 5 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Data source: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Madrid, Spain